Skip to main content

Table 2 Monoclonal antibodies directed against non-CD20 surface epitopes

From: New antibody approaches to lymphoma therapy

mAB Target Structure Unique properties Indication tested Phase of development References
Epratuzumab CD22 Humanized IgG1 Enhanced ADCC, no PCD NHL/DLBCL Phase 1/2 [50]-[56]
Medi 551 CDI9 Afucosylated humanized IgG1 Enhanced ADCC, no CDC NHL/DLBCL/ALL Phase 1/2 [60],[61]
Lucatumumab CD4O Humanized IgG1 Also being tested in myeloma. ADCC NHL/CLL/HL/MZL/MALT Phase 1/2 [64],[69],[70]
Dacetuzumab CD4O Humanized IgG1 Partial agonist. Enhanced ADCC/CDC/PCD DLBCL Phase 1 [71]-[76]
Alemtuzumab (Campath®) CD 52 Humanized IgG1 Enhanced ADCC/CDC/PCD CLL/T-Cell NHL Approved for del17p CLL Phase 2/3 [81]-[89]
Mogalizumab CCR4 Afucosylated humanized IgG1 Enhanced ADCC PTCL/CTCL Phase 1/2 [91]-[98]
Pidilizumab (CT-011) PD-1* Humanized lgG1 Kappa recombinant Reverses T-cell anergy NHL/DLBCL Phase 1/2 [101]-[113]
Blinatumomab BiTE (CD3/CD19) Single-chain bispecific antibody construct with variable regions of two antibodies. Bispecific T-cell Engager DLBCL/ALL Phase 2/3 [118]-[120]
  1. ADCC: Antibody dependent cellular cytotoxicity; ALL: Acute lymphoblastic leukemia; BiTE: Bispecific T-cell Engager; CDC: Complement dependent cytotoxicity; CLL: Chronic lymphocytic leukemia; CTCL: Cutaneous T Cell Lymphoma; DLBCL: Diffuse large B cell lymphoma; HL: Hodgkin lymphoma; mAB: Monoclonal antibody; MALT: Mucosa associated Lymphoid tissue lymphoma; Moa: Mechanism of action; MZL: Marginal zone lymphoma; NHL: Non Hodgkin lymphoma; PCD: programmed cell death; PTCL: Peripheral T Cell Lymphoma.
  2. *PD1 is mainly expressed on regulatory T cell surface, while its ligand PDL-1 is often expressed on malignant cells. Stimulation of this pathway results in immune anergy towards malignant cells.